Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Local Stocks

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

48.68 -0.06 (-0.12%)

Official Closing Price Updated: 4:10 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

39 40 Next >

GSK (GSK) Q3 2026 Earnings Call Transcript ↗

October 28, 2026

Specialty medicines surged 15% as oncology and respiratory treatments drove growth.

Via The Motley Fool

Topics Earnings Economy

What GSK (GSK) Said on Its Q3 Earnings Call ↗

October 28, 2026

GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit...

Via MarketBeat

Topics Earnings Intellectual Property

GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update ↗

October 27, 2026

GSK (NYSE:GSK) highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC...

Via MarketBeat

Topics Intellectual Property

GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow ↗

May 19, 2026

Via Chartmill

Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market Does ↗

October 14, 2026

These three dividend stocks sell products people buy out of necessity rather than by choice, making their next payout increase feel less like hope and more like a certainty.

Via The Motley Fool

Topics Economy

GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care ↗

September 23, 2026

GSK (NYSE:GSK) is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the...

Via MarketBeat

Topics Artificial Intelligence Intellectual Property

GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape ↗

September 23, 2026

GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company’s growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain...

Via MarketBeat

Topics Economy Intellectual Property

GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline ↗

September 16, 2026

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of...

Via MarketBeat

Topics Intellectual Property

GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff ↗

September 13, 2026

GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through...

Via MarketBeat

Topics Artificial Intelligence Intellectual Property

Gibson Energy (GEI) Q2 2026 Earnings Call Transcript ↗

July 28, 2026

Record infrastructure EBITDA and improved marketing guidance signal strong momentum.

Via The Motley Fool

Topics Earnings

GSK Q2 Earnings Call Highlights ↗

July 28, 2026

GSK (NYSE:GSK) reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and...

Via MarketBeat

Topics Earnings Intellectual Property

MarketBeat Week in Review – 06/08 - 06/12 ↗

June 13, 2026

Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum

Via MarketBeat

Topics Economy Initial Public Offering

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗

June 11, 2026

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

Via MarketBeat

Topics Intellectual Property

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗

May 29, 2026

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

Via The Motley Fool

Topics Regulatory Compliance

This Income Fund Just Completely Exited Its $37 Million Stake in Algonquin Power. Why? ↗

May 18, 2026

Algonquin serves approximately 1.3 million customer connections across the United States, Canada, Bermuda, and Chile through its regulated utility network.

Via The Motley Fool

Topics Regulatory Compliance

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat ↗

May 02, 2026

Via MarketBeat

Mondrian Dumps 5.5 Million Yum China Shares Worth $284.6 Million ↗

April 29, 2026

Yum China operates over 12,000 restaurants across 1,700 cities, serving quick-service and casual dining to mass-market consumers.

Via The Motley Fool

Nvidia Rival Cerebras Files for an IPO: What Investors Should Know ↗

April 20, 2026

Cerebras Systems is a fast-growing AI chipmaker whose customers include ChatGPT maker OpenAI, Amazon, and Meta Platforms.

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering

3 Bargain-Cheap Small Caps Worth a Second Look ↗

April 09, 2026

Via MarketBeat

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability

March 31, 2026

As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the...

Via Finterra

Topics Initial Public Offering

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...

Via MarketMinute

Topics Intellectual Property

The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery

March 16, 2026

The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper...

Via MarketMinute

Topics Artificial Intelligence Initial Public Offering Stocks

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape

March 16, 2026

In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health...

Via MarketMinute

Topics Artificial Intelligence Lawsuit

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗

March 16, 2026

Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs.

Via Benzinga

The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology

March 06, 2026

On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a...

Via Finterra

Topics Initial Public Offering Intellectual Property

Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era

March 05, 2026

Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level...

Via Finterra

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.